Comparative Pharmacology
Head-to-head clinical analysis: DITATE DS versus METHYLPREDNISOLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DITATE DS versus METHYLPREDNISOLONE.
DITATE-DS vs METHYLPREDNISOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DITATE-DS is a combination of dexamethasone, a corticosteroid with anti-inflammatory and immunosuppressant properties, and trimethoprim, a folate antagonist. Dexamethasone acts by binding to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response. Trimethoprim inhibits dihydrofolate reductase, blocking bacterial folate synthesis and exerting antibacterial effects.
Glucocorticoid receptor agonist; inhibits phospholipase A2, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell activity.
1 tablet (0.5 mg dexamethasone/5 mg cyproheptadine) orally every 8 hours, maximum 3 tablets daily.
4-48 mg/day orally in divided doses; 10-40 mg IV/IM bolus, then 10-40 mg IV q4-6h; high-dose IV pulse: 1 g/day for 3 days.
None Documented
None Documented
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Deslanoside
"Methylprednisolone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethylprednisolone + Acetyldigitoxin
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Plasma: 2.5-3.5 hours; biological half-life (tissue): 18-36 hours due to glucocorticoid receptor-mediated effects; clinical context: anti-inflammatory effects persist beyond plasma clearance
Renal (50-60% as unchanged drug and metabolites), biliary/fecal (40-50% as metabolites and unchanged drug).
Renal (primarily as inactive metabolites, <10% unchanged); minor biliary/fecal elimination
Category C
Category D/X
Corticosteroid
Corticosteroid
"Methylprednisolone may decrease the cardiotoxic activities of Acetyldigitoxin."